ATP6AP2 (the prorenin receptor) has emerged as a biomarker in multiple cancers, including melanoma (Wang et al., 2020), and SOD2 has been reported to play context-dependent roles in melanoma, with studies supporting both tumor-suppressive and pro-tumorigenic effects (Carvalho et al., 2022). This evidence concerns the gene ATP6AP2 and melanoma.